Comprehensive Allergy Immunotherapy Market Forecast 2025-2034: Growth Trends and Strategic Shifts

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

Allergy Immunotherapy Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for allergy immunotherapy has undergone swift growth in the past few years. The market is projected to surge from $2.88 billion in 2024 to $3.17 billion in 2025, depicting a compound annual growth rate (CAGR) of 10.2%. The growth noted during the historic period is largely due to the rising prevalence of allergic diseases, developments in immunotherapy methods, heightened patient awareness, governmental actions, and enhancements in research and development.

Allergy Immunotherapy Market Size Forecast: What's the Projected Valuation by 2029?
The market size of allergy immunotherapy is predicted to experience fast expansion in the forthcoming years, and it will escalate to $5.07 billion in 2029, with a compound annual growth rate (CAGR) of 12.4%. The growth over the forecasted period will be driven by elements like a surging global allergy burden, endorsement from healthcare policies, rising adoption of immunotherapy, introduction of new markets and untouched areas, as well as an upsurge in health care expenditure. The forecasted period will also witness trends like progress in treatment technology, surge in allergy cases, an increase in patient consciousness and education, telemedicine and distant monitoring, and personalized treatment strategies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/allergy-immunotherapy-global-market-report

What Are the Drivers Transforming the Allergy Immunotherapy Market?
The escalating incidence of allergic conditions is predicted to drive the expansion of the allergy immunotherapy market. These conditions involve the immune system excessively reacting to specific antigens. Autoimmune diseases occur when immunity is wrongfully aimed against internal body parts (self). For those suffering from allergic disorders such as IgE-mediated allergic rhinitis and allergic asthma induced by inhaling allergens, such as pollens and house dust mites (HDMs), allergy immunotherapy is readily available. To illustrate, the Medicines and Healthcare Products Regulatory Agency (MHRA), an executive agency based in the UK, reported in August 202 that during 2022-23, more than 25,000 allergy and anaphylaxis admissions were recorded in English hospitals, a figure more than double that of the previous two decades. Furthermore, the Food Standards Agency, a British government department, revealed in its May 2024 Patterns and Prevalence of Adult Food Allergy (PAFA) report that approximately 6% or roughly 2.4 million adults in the UK have food allergies. Hence, the increasing incidence of allergic conditions is propelling the growth of the allergy immunotherapy market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9416&type=smp

What Long-Term Trends Will Define the Future of the Allergy Immunotherapy Market?
Top firms active in the allergy immunotherapy market are utilizing innovations like artificial intelligence (AI)-enabled allergy component testing to maintain their competitive edge. This state-of-the-art testing platform, which leverages component resolved diagnostics (CRD) technology, is employed to diagnose a diverse array of allergies. In May 2023, for example, Metropolis Healthcare Limited, an Indian medical lab company, introduced AI-assisted allergy component testing. This fourth-gen allergy diagnostic tool harnesses the power of AI to aid clinicians in making informed clinical decisions. It offers valuable insights and aids in customizing the most effective treatment plans for allergy-related ailments. Not only this, but it can predict the success of allergy immunotherapy vaccines, thereby determining whether they'll be effective.

Which Segments in the Allergy Immunotherapy Market Offer the Most Profit Potential?
The allergy immunotherapy market covered in this report is segmented -

1) By Allergy Type: Allergic Rhinitis, Asthma, Food Allergy, Venom Allergy, Other Allergy Types
2) By Treatment: Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy, Specific Immunotherapy (SIT)
3) By Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:
1) By Allergic Rhinitis: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis
2) By Asthma: Allergic Asthma, Non-Allergic Asthma
3) By Food Allergy: Peanut Allergy, Tree Nut Allergy, Milk Allergy, Egg Allergy, Other Food Allergies
4) By Venom Allergy: Insect Sting Allergy, Other Venom Allergies
5) By Other Allergy Types: Allergic Conjunctivitis, Eczema, Drug Allergies, Other Environmental Allergies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=9416&type=smp

Which Firms Dominate the Allergy Immunotherapy Market by Market Share and Revenue in 2025?
Major companies operating in the allergy immunotherapy market include LETI Pharma, Stallergenes Greer International AG, Allergy Therapeutics plc, ALK-Abelló A/S, HAL Allergy B.V., DBV Technologies, Circassia Pharmaceuticals Inc., Jubilant HollisterStier LLC, Allergopharma GmbH & Co. KG, Biomay AG, Anergis SA, HollisterStier Allergy, Mylan N.V., Adamis Pharmaceuticals Corporation, Desentum Oy, WOLW Pharma Limited, AllerGenics Inc., Greer Laboratories Inc., Aimmune Therapeutics Inc., Reliant Laboratories Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Danaher Corporation, QIAGEN NV, Merck & Co. Inc., Pfizer Inc., Novartis AG, GlaxoSmithKline plc, AstraZeneca plc, Sanofi SA, Teva Pharmaceutical Industries Ltd., Endo Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd.

Which Regions Offer the Highest Growth Potential in the Allergy Immunotherapy Market?
Europe was the largest region in the allergy immunotherapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the allergy immunotherapy market report during the forecast period. The regions covered in the allergy immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9416

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.